DİLER US ALTAY, Özlem ÖZDEMİR, TEVFİK NOYAN, Sefa YÜKSEL, Burhanettin Sertaç AYHAN

Subklinik hipotroidi hasta serumlarında homosistein ve irisin seviyelerinin tanısal öneminin belirlenmesi

Amaç: Bu çalışmanın amacı, subklinik hipotiroidi (SH) hastalarının serumlarında irisin ve homosistein (Hcy)düzeylerinin tanısal önemini belirlemektir.Yöntemler: Çalışmada 80 kişi değerlendirildi. Hasta grubuna, SH tanısı konmuş 40 hasta ve kontrol grubuna 40sağlıklı birey dahil edildi. Kan örnekleri toplandı ve enzim bağlı immünosorbent testi (ELISA) kullanılarak serum irisinve Hcy düzeyleri belirlendi. Tiroid uyarıcı hormon (TSH), serbest triiyodotironin (fT3), serbest tiroksin (fT4)düzeyleri Cobas e 601 otoanalizörü kullanılarak kemilüminesans yöntemiyle ölçüldü.Bulgular: SH hastalarında Irisin, Hcy, TSH düzeyleri kontrol grubuna göre anlamlı olarak yüksek bulundu (sırasıyla p =0.0001, p = 0.0001, p = 0.0001). Ayrıca, İrisin ve Hcy seviyeleri TSH seviyeleri kadar spesifik ve sensitifti. SH için en iyikesme noktaları, İrisin için > 14.43 ng / mL, Hcy için > 13.53 nmol / ml ve TSH için > 4.11 uUI / mL idi.

Determining the diagnostic significance of irisin and homocysteine levels in the serum of patients with subclinical hypothyroidism

Objectives: The aim of this study was to determine the diagnostic significance of irisin and homocysteine (Hcy) levels in the serum of patients with subclinical hypothyroidism (SH). Methods: In the study, 80 individuals were evaluated. The patient group included 40 subjects diagnosed with SH and the control group 40 healthy individuals. Blood specimens were collected and serum irisin and Hcy levels were determined using enzyme-linked immunosorbent assay (ELISA). Thyroid stimulating hormone (TSH), free triiodothyronine (fT3), free thyroxine (fT4) levels were measured by chemiluminescent method using Cobas e 601 autoanalyzer Results: Irisin, Hcy and TSH levels in SH patients were significantly higher compared with the control group (p=0.0001, p=0.0001, p=0.0001, respectively). Also, irisin and hcy levels were closely sensitive and specific even TSH levels. The best cut-off points for irisin were >14.43 ng/mL, hcy were >13.53 nmol/mL, TSH >4.11µUI/mL for SH. Conclusion: Irisin and Hcy may be used as a diagnostic biomarker for SH.

PDF

___

1. Cojić M, Cvejanov-Kezunović L. Subclinical Hypothyroidism – Whether and When To Start Treatment. Maced J Med Sci. 2017; 15; 5: 1042-6.
2. Moreno-Navarrete JM, Ortega F, Serrano M, et al. Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. J Clin Endocrinol Metab. 2013; 98: E769-78.
3. Ateş İ, Altay M, Topçuoğlu C, Yılmaz FM. Circulating levels of irisin is elevated in hypothyroidism, a casecontrol study. Arch Endocrinol Metab. 2016; 60: 95- 100.
4. Zybek-Kocik A, Sawicka-Gutaj N, Wrotkowska E, Sowiński J, Ruchała M. Time-dependent irisin concentration changes in patients affected by overt hypothyroidism. Endokrynol Pol. 2016; 67: 476-80.
5. Iizuka K, Machida T, Hirafuji M. Skeletal muscle is an endocrine organ. J Pharmacol Sci 2014; 125: 125e131.
6. Hofmann T, Elbelt U, Stengel A. Irisin as a musclederived hormone stimulating thermogenesisea critical update. Peptides 2014; 54: 89e100.
7. Moreno M, Moreno-Navarrete JM, Serrano M, et al. Circulating irisin levels are positively associated with metabolic risk factors in sedentary subjects. PLoS One. 2015; 10: e0124100.
8. Panagiotou G, Mu L, Na B, Mukamal KJ, Mantzoros CS. Circulating irisin, omentin-1, and lipoprotein subparticles in adults at higher cardiovascular risk. Metabolism. 2014; 63: 1265-71.
9. Kuloglu T, Aydin S, Eren MN, et al. Irisin: a potentially candidate marker for myocardial infarction. Peptides. 2014; 55C: 85–91.
10. Morris MS, Bostom AG, Jacques PF, Selhub J, Rosenberg IH. Hyperhomocysteinemia and hypercholesterolemia associated with hypothyroidism in the third US National Health and Nutrition Examination Survey. Atherosclerosis. 2001; 155: 195– 200.
11. Bamashmoos SA, Al-Nuzaily MA, Al-Meeri AM, Ali FH. Relationship between total homocysteine, total cholesterol and creatinine levels in overt hypothyroid patients. Springerplus. 2013; 30: 423.
12. Maron BA, Loscalzo J. The treatment of hyperhomocysteinemia. Annu Rev Med 2009; 60: 39– 54.
13. Selmer C, Olesen JB, Hansen ML,et al. Subclinical and overt thyroid dysfunction and risk of all-cause mortality and cardiovascular events: a large population study. J Clin Endocrinol Metab 2014; 99: 2372–82.
14. Nanchen D, Gussekloo J, Westendorp RG, et al. Subclinical thyroid dysfunction and the risk of heart failure in older persons at high cardiovascular risk. J Clin Endocrinol Metab 2012; 97: 852–61.
15. Gencer B, Collet TH, Virgini V, et al. Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohorts. Circulation 2012; 126: 1040–9.
16. Vargas-Uricoechea H, Bonelo-Perdomo A. Thyroid Dysfunction and Heart Failure: Mechanisms and Associations. Curr Heart Fail Rep. 2017; 14: 48–58.
17. McAninch EA, Bianco AC. Thyroid hormone signaling in energy homeostasis and energy metabolism. Ann N Y Acad Sci. 2014; 1311: 77–87.
18. Zarković M. The deficit of thyroid hormones - effect on cardiovascular and cognitive functions. (srb. Deficit tiroidnih hormona – uticaj na kardiovaskularne i kognitivne funkcije.) Medical Gazette Special hospital for thyroid gland diseases and metabolic diseases Zlatibor (srb. Medicinski glasnik Specijalna bolnica za bolesti štitaste žlezde i bolesti metabolizma Zlatibor). 2007; 12: 47-53.
19. Klein I, Ojamaa K. Thyroid hormone and cardiovascular System. N Engl J Med. 2001; 344: 501-9.
20. Ichiki T. Thyroid hormone and atherosclerosis. Vascul Pharmacol. 2010; 52: 151–6.
21. Cappola AR, Ladenson PW. Hypothyroidism and atherosclerosis. J Clin Endocrinol Metab. 2003; 88: 2438–44.
22. Huh JY, Panagiotou G, Mougios V, et al. FNDC5 and irisin in humans: I.Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metab Clin Exp 2012; 61: 1725–38.
23. Samy DM, Ismail CA, Nassra RA. Circulating irisin concentrations in rat models of thyroid dysfunction – effect of exercise. Metabolism 2015; 64: 804–13.
24. Ruchala M, Zybek A, Szczepanek-Parulska E. Serum irisin levels and thyroid function – Newly discovered association. Peptides. 2014; 60: 51-5.
25. Yalcin MM, Akturk M, Tohma Y, et al. Irisin and myostatin levels in patients with Graves' disease. Arch Med Res 2016; 47: 471-5.
26. Zybek-Kocik A, Sawicka-Gutaj N, Wrotkowska E, Sowiński J, Ruchała M. Time-dependent irisin concentration changes in patients affected by overt hypothyroidism. Endokrynol Pol 2016; 67: 476-80
27. Ellefsen S, Vikmoen O, Slettaløkken G, et al. Irisin and FNDC5: effects of 12-week strength training, and relations to muscle phenotype and body mass composition in untrained women. Eur J Appl Physiol 2014: 114; 1875–88.
28. Stengel A, Hofmann T, Goebel-Stengel M, et al. Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity – correlation with body mass index. Peptides 2013; 39: 125–30.